Regeneron Historical Balance Sheet

REGN
 Stock
  

USD 628.71  4.81  0.77%   

Trend analysis of Regeneron Pharmaceuticals balance sheet accounts such as Current Assets of 15.1 B, Assets Non Current of 3.7 B, Cash and Equivalents of 3.1 B or Total Debt of 349.8 M provides information on Regeneron Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Regeneron Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Regeneron Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year. Financial Statement Analysis is much more than just reviewing and breaking down Regeneron Pharmaceuticals prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regeneron Pharmaceuticals is a good buy for the upcoming year.
Additionally, take a look at Your Equity Center.
  

About Regeneron Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Regeneron Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Regeneron Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Regeneron Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Regeneron currently owns. An asset can also be divided into two categories, current and non-current.

Regeneron Pharmaceuticals Balance Sheet Chart

Regeneron Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Regeneron Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
Regeneron Pharmaceuticals Assets Non Current are quite stable at the moment as compared to the past year. The company's current value of Assets Non Current is estimated at 3.68 Billion. Cash and Equivalents is expected to rise to about 3.1 B this year, although the value of Accumulated Other Comprehensive Income will most likely fall to (11.9 M).

Total Assets

Total assets refers to the total amount of Regeneron Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Regeneron Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; Investments; [Intangibles]; Property Plant and Equipment Net; Tax Assets and Trade and Non Trade Receivables.

Current Assets

Current assets of Regeneron Pharmaceuticals include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Regeneron Pharmaceuticals. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Shareholders Equity

A principal component of the balance sheet; in addition to Total Liabilities and Total Assets; that represents the total of all stockholders' equity (deficit) items; net of receivables from officers; directors; owners; and affiliates of the entity which are attributable to the parent.

Total Liabilities

Deferred Income Tax is recorded on Regeneron Pharmaceuticals balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on Regeneron Pharmaceuticals books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are Total Debt; Deferred Revenue; Trade and Non Trade Payables; Deposit Liabilities; and Tax Liabilities.
Most accounts from Regeneron Pharmaceuticals balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Additionally, take a look at Your Equity Center.Regeneron Pharmaceuticals Assets Non Current are quite stable at the moment as compared to the past year. The company's current value of Assets Non Current is estimated at 3.68 Billion. Cash and Equivalents is expected to rise to about 3.1 B this year, although the value of Accumulated Other Comprehensive Income will most likely fall to (11.9 M).
 2019 2020 2021 2022 (projected)
Receivables2.1 B3.71 B6.04 B6.51 B
Inventories1.42 B1.92 B1.95 B2.11 B

Regeneron Pharmaceuticals balance sheet Correlations

0.920.980.970.970.740.960.10.48-0.430.740.960.770.750.770.730.970.960.680.730.730.640.78
0.920.950.980.980.620.970.00.44-0.380.610.970.630.620.630.610.970.980.570.610.610.570.62
0.980.950.980.980.720.980.080.51-0.390.70.980.730.720.720.70.980.980.660.710.710.640.72
0.970.980.981.00.720.990.050.5-0.420.711.00.740.730.730.70.981.00.660.710.710.640.73
0.970.980.981.00.70.990.050.49-0.40.690.990.710.70.710.680.980.990.640.690.690.630.7
0.740.620.720.720.70.660.410.79-0.260.980.710.991.00.960.990.730.710.960.991.00.950.94
0.960.970.980.990.990.660.060.49-0.350.650.980.680.670.660.660.970.980.620.660.660.590.65
0.10.00.080.050.050.410.060.460.710.350.040.370.420.310.480.080.030.50.390.380.490.28
0.480.440.510.50.490.790.490.460.050.680.50.720.80.750.810.510.50.730.830.790.880.58
-0.43-0.38-0.39-0.42-0.4-0.26-0.350.710.05-0.32-0.42-0.33-0.27-0.4-0.18-0.41-0.42-0.12-0.27-0.28-0.08-0.45
0.740.610.70.710.690.980.650.350.68-0.320.70.990.960.920.970.730.690.980.950.980.90.95
0.960.970.981.00.990.710.980.040.5-0.420.70.720.720.720.690.960.990.650.70.70.630.72
0.770.630.730.740.710.990.680.370.72-0.330.990.720.990.970.980.750.720.960.980.990.910.97
0.750.620.720.730.71.00.670.420.8-0.270.960.720.990.980.990.740.710.940.990.990.940.95
0.770.630.720.730.710.960.660.310.75-0.40.920.720.970.980.940.740.720.860.960.950.880.96
0.730.610.70.70.680.990.660.480.81-0.180.970.690.980.990.940.720.690.980.990.990.960.92
0.970.970.980.980.980.730.970.080.51-0.410.730.960.750.740.740.720.990.680.720.720.650.74
0.960.980.981.00.990.710.980.030.5-0.420.690.990.720.710.720.690.990.640.70.70.630.71
0.680.570.660.660.640.960.620.50.73-0.120.980.650.960.940.860.980.680.640.940.960.930.89
0.730.610.710.710.690.990.660.390.83-0.270.950.70.980.990.960.990.720.70.941.00.950.92
0.730.610.710.710.691.00.660.380.79-0.280.980.70.990.990.950.990.720.70.961.00.950.93
0.640.570.640.640.630.950.590.490.88-0.080.90.630.910.940.880.960.650.630.930.950.950.82
0.780.620.720.730.70.940.650.280.58-0.450.950.720.970.950.960.920.740.710.890.920.930.82
Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals balance sheet Accounts

201720182019202020212022 (projected)
Inventories726.14 M1.15 B1.42 B1.92 B1.95 B2.11 B
Receivables1.54 B1.72 B2.1 B3.71 B6.04 B6.51 B
Accounts Payable178.18 M218.2 M418.1 M475.5 M564 M608.53 M
Total Assets8.76 B11.73 B14.81 B17.16 B25.43 B27.44 B
Current Assets4.34 B6.45 B7.69 B9.78 B14.01 B15.12 B
Cash and Equivalents812.73 M1.47 B1.62 B2.19 B2.89 B3.11 B
Shareholders Equity6.14 B8.76 B11.09 B11.03 B18.77 B20.25 B
Total Liabilities2.62 B2.98 B3.72 B6.14 B6.67 B7.19 B
Current Liabilities1.14 B1.44 B2.1 B2.7 B3.93 B4.24 B

Be your own money manager

Our tools can tell you how much better you can do entering a position in Regeneron Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Breakdown Now

   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

Currently Active Assets on Macroaxis

Additionally, take a look at Your Equity Center. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.73
Market Capitalization
68.3 B
Quarterly Revenue Growth YOY
-0.44
Return On Assets
0.18
Return On Equity
0.32
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.